As shown in case 3, the addition of an SGLT2 inhibitor to the basal-bolus insulin regimen resulted in lower doses of preprandial rapid-acting insulin being utilized leading to less hypoglycemia and improved though not ideal glycemic control [11]. The gene discussed is INS; the disease is Hypoglycemia.